Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in NRG1-fused NSCLC
NCT04814056Phase 4Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04814056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814056.